Literature and evidence database
Find the source, the model and the boundary.
Search source records connected to the product-family knowledge base. Filter by category, product, publication year, research type, study model and editorial evidence tier.
Product evidence maps
A focused source set for each product.
Search and filter
Evidence records
Narrow the records by product, year or study model. Open each source to check its results and limitations.
Performance-enhancing peptides modulating the GH-IGF1 axis
Critical review. 2026. PMID 42395176.
EGRIFTA WR (tesamorelin) prescribing information
U.S. Food and Drug Administration. 2025 labeling record for BLA 022505.
GHRP-6 in doxorubicin-induced injury
Preclinical study. 2024. PMID 38873418.
Enzymatic and serum stability of GHRP and GHRH-related peptides
Analytical study. 2023. PMID 37688464.
Hexarelin alleviates apoptosis in ischemic acute kidney injury
Preclinical study. 2023. PMID 37710348.
Recombinant expression of IGF-1 and LR3 IGF-1 in Pichia pastoris
Biotechnology study. 2023. PMID 37261455.
Advances in detection of GHRH synthetic analogs
Analytical review. 2021. PMID 34665524.
Glycine-modified growth hormone secretagogues identified in seized doping material
Analytical study. 2019. PMID 30136411.
The Safety and Efficacy of Growth Hormone Secretagogues
Sigalos JT, Pastuszak AW. 2018. PMID 28400207.
Randomized ipamorelin study after bowel resection
Beck DE, et al. International Journal of Colorectal Disease. 2014. PMID 25331030.
The cardiovascular action of hexarelin
Mao Y, et al. Journal of Geriatric Cardiology. 2014. PMID 25278975.
MK-0677 phase IIb hip-fracture study
Adunsky A, et al. Archives of Gerontology and Geriatrics. 2011. PMID 21067829.
MK-677 in healthy older adults
Nass R, et al. Annals of Internal Medicine. 2008. PMID 18981485.
Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Clinical perspective. 2006. PMID 18046908.
Prolonged stimulation of GH and IGF-I secretion by CJC-1295
Teichman SL, et al. J Clin Endocrinol Metab. 2006. PMID 16352683.
Pulsatile GH secretion persists during CJC-1295 stimulation
Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006. PMID 17018654.
Pralmorelin: GHRP-2 drug profile
AdisInsight profile. 2004. PMID 15230633.
Action of long(R3)-IGF-1 on protein metabolism in beef heifers
Animal study. 1999. PMID 10370861.
Growth hormone-releasing peptides
Ghigo E, et al. 1997. PMID 9186261.
GHRP-6 response in hypothalamopituitary disconnection
Human endocrine study. 1995. PMID 7883854.
Potent long-acting GRF analogues
Rivier J, et al. Ann N Y Acad Sci. 1988. PMID 3133968.
GRF1-29 compared with longer human GRF fragments
Losa M, et al. Klin Wochenschr. 1984. PMID 6240568.
Human growth hormone
Foundational review. 1968. PMID 4914846.
Certain Bulk Drug Substances That May Present Significant Safety Risks
U.S. FDA. Current compounding safety-information page.
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension
Falutz J, et al. Journal of Acquired Immune Deficiency Syndromes. PMID 20101189 · DOI 10.1097/QAI.0b013e3181cbdaff
GHRP-2 and food intake in healthy men
Seven-person human crossover physiology study; PMID 15699539.
Five-day GHRP-2 treatment in healthy men
Nine-person repeated-response study; PMID 9820615.
PubChem Pralmorelin record
Sequence, stereochemistry, formula and molecular weight; CID 6918245.
WADA 2026 Prohibited List
Official list prohibits mechano growth factors.
GHRH dependence of the GHRP-6 response
Nine-person antagonist study; PMID 9543138.
Editorial methodology
How records are classified
Records are deduplicated by source URL and linked to every relevant product family. Study type and model are inferred from the citation and editorial evidence label, then reviewed during content QA.
Read the full editorial, AI-assistance and correction policy →
Labels and databases supporting regulatory status, formulation or chemical identity.
Controlled trials, systematic reviews and other clinical records with population-specific interpretation.
Animal, cell, analytical and mechanistic records that cannot establish human outcomes.
Narrative reviews, registries and sponsor reports kept visibly distinct from peer-reviewed outcomes.
Use the records
